查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球液態切片市場：按產品和服務、循環生物標記、技術、應用、樣本類型 - 預測（至 2029 年）
市場調查報告書
商品編碼
1478563

全球液態切片市場：按產品和服務、循環生物標記、技術、應用、樣本類型 - 預測（至 2029 年）

Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (CTC, ctDNA, cfDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-cancer (NIPT, Infectious)), Sample Type (Blood) - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 328 Pages | 訂單完成後即時交付

價格
簡介目錄

液態切片市場規模預計將從 2024 年的 64 億美元增加到 2029 年的 113 億美元，預測期內複合年成長率為 11.9%。

與傳統的切開切片檢查方法相比，液態切片具有許多優勢，包括非侵入性、降低手術成本、容易疾病監測以及早期發現癌症。這些優點正在推動最終用戶對液態切片的接受。相對於傳統切片檢查方法，液態切片的日益認可和越來越多的採用正在推動液態切片產品和服務的重大進步。

調查範圍
調查年份 2022-2029
基準年 2023年
預測期 2024-2029
單元 金額（美元）
部分 產品與服務·循環生物標記·臨床應用·技術·應用·樣本類型·最終用戶
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲、海灣合作理事會國家

按產品/服務分類，檢測試劑套件細分市場預計將在預測期內呈現最高成長率：

在產品和服務方面，檢測試劑套件產業經歷了顯著成長。由於需要重複購買檢測試劑套件，因此預計會有高成長率。此外，各種試劑和套件的可用性、各種檢測方法的便利性以及癌症盛行率的上升是推動該行業成長的其他主要因素。

根據臨床應用，早期癌症篩檢領域預計將在預測期內達到最高成長率：

由於對早期癌症篩檢的研究日益關注以及該領域資金的增加，推動了液態切片技術在早期癌症篩檢中的快速採用。這項研究勢頭導致了液態切片在早期癌症篩檢中的更廣泛應用並提高了性能，進一步推動了該領域的發展。

按地區分類，亞太地區是成長最快的地區：

預計亞太地區液態切片市場的複合年成長率最高。該地區學術機構、研究機構和醫療保健公司之間不斷加強的研究合作正在促進液態切片技術的進步和商業化。

本報告調查了全球液態切片市場，並提供了市場概況、市場影響因素分析、技術和專利趨勢、案例研究、市場規模趨勢和預測、各個細分市場和地區的詳細分析以及競爭狀況，並編制了主要企業。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
    • 任務
  • 價格分析
  • 專利分析
  • 價值鏈分析
  • 供應鏈分析
  • 貿易分析
  • 生態系分析
  • 波特五力分析
  • 主要相關利益者和採購標準
  • 監管狀況
  • 技術分析
  • 主要會議及活動
  • 影響客戶業務的趨勢/干擾
  • 投資金籌措場景
  • 案例研究分析

第6章液態切片市場：按產品和服務

  • 檢測套件
  • 裝置
  • 服務

第7章液態切片市場：透過循環生物標記物

  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 細胞外DNA
  • 細胞外囊泡
  • 其他

第8章液態切片市場：依技術分類

  • 使用 NGS 並行分析多個基因
  • 使用 PCR 進行單基因分析

第9章液態切片市場：依應用分類

  • 癌症治療
    • 肺癌
    • 乳癌
    • 大腸直腸癌
    • 攝護腺癌
    • 黑色素瘤
    • 其他
  • 非癌症治療
    • 非侵入性產前檢測
    • 器官移植
    • 傳染病檢查

第10章液態切片市場：依臨床應用

  • 治療方法選擇
  • 治療監測
  • 早期癌症篩檢
  • 復發監測

第11章液態切片市場：按樣本類型

  • 血液樣本
  • 其他

第12章液態切片市場：依最終用戶分類

  • 參考實驗室
  • 醫院/醫生實驗室
  • 學術研究中心
  • 其他

第13章液態切片市場：按地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲
  • 海灣合作理事會國家

第14章競爭格局

  • 主要企業/主要企業策略
  • 收益分析
  • 市場佔有率分析
  • 企業評價矩陣：主要企業
  • 企業評價矩陣：新興企業/中小企業
  • 液態切片商評估和財務指標
  • 品牌/產品比較
  • 競爭場景

第15章 公司簡介

  • 主要企業
    • NATERA, INC.
    • QIAGEN
    • MYRIAD GENETICS, INC.
    • ILLUMINA, INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • THERMO FISHER SCIENTIFIC INC.
    • GUARDANT HEALTH
    • BIO-RAD LABORATORIES, INC.
    • EXACT SCIENCES CORPORATION
    • SYSMEX CORPORATION
    • BIOCEPT, INC.
    • MDXHEALTH
    • PERSONALIS, INC.
  • 其他公司
    • NEOGENOMICS LABORATORIES
    • EPIGENOMICS AG
    • ANGLE PLC
    • MENARINI-SILICON BIOSYSTEMS
    • LUNGLIFE AI, INC.
    • VORTEX BIOSCIENCES
    • BIO-TECHNE
    • MESA LABS, INC.
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • MEDGENOME
    • STRAND
    • FREENOME HOLDINGS, INC.
    • LUCENCE HEALTH INC.

第16章附錄

簡介目錄
Product Code: MD 4456

The liquid biopsy market is valued at an estimated USD 6.4 billion in 2024 and is projected to reach USD 11.3 billion by 2029 at a CAGR of 11.9% during the forecast period. Liquid biopsy presents numerous advantages compared to conventional incisional biopsy techniques, including its non-invasive nature, decreased procedural expenses, easy disease montoring, and early detection of cancer at its initial stages. These advantages have fueled the acceptance of liquid biopsy procedures by end users. The increasing adoption and acknowledgment of liquid biopsy's benefits over traditional biopsy methods are driving significant advancements in liquid biopsy products and services.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsProduct & service, circulating biomarker, clinical application, technology, application, sample type, and end user
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries

"Assay kits segment accounted for the highest growth rate in the liquid biopsy market, by product & service, during the forecast period."

Based on product & service, the liquid biopsy market is bifurcated into assay kits, instruments, and services. The assay kits segment in the liquid biopsy market is experiencing substantial growth. The recurrent requirement and purchase of these assay kits is one of the primary reasons for the high growth rate of this market segment. The availability of a wide range of reagents and kits, easy accessibility to a wide range of assays, and the rising prevalence of cancer are other major factors driving the growth of the liquid biopsy assay kits market.

"Early cancer screening segment accounted for the highest growth rate in the liquid biopsy market, by clinical application, during the forecast period."

The liquid biopsy market is segmented into into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring, based on clinical application. Early cancer screening segment is expected to account for the highest CAGR during the forecast period. The rapid adoption of liquid biopsy technologies for early cancer screeening is fueled by the growing research focus on early cancer detection, coupled with increased funding in this area. This research momentum is translating into a broader range of applications and improved performance of liquid biopsy in early cancer screening, further boosting its growth in this segment.

"Asia Pacific: The fastest-growing region in liquid biopsy market."

The worldwide market for liquid biopsy is categorized into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. The Asia Pacific region is poised to experience the most notable CAGR within the liquid biopsy market. Increasing collaborations between academic institutions, research organizations, and healthcare companies in the Asia Pacific region contribute to the advancement and commercialization of liquid biopsy technologies.

The break-up of the profile of primary participants in the liquid biopsy market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Guardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).

Research Coverage:

This research report categorizes the liquid biopsy market by product & service (assay kits, instruments, and services), by circulating biomarker (circulating tumor cells, circulating tumor DNA, cell-free DNA, extracellular vesicles and other circulating biomarkers), by technology (multi-gene parallel analysis using NGS and single-gene analysis using PCR), by application (cancer applications [lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, and other cancers] and non-cancer applications [non-invasive prenatal testing, organ transplantation, and infectious disease testing]), by clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), by sample type (blood and other sample types, by end user (reference laboratories, hospitals and physician laboratories, academic & research centers, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the liquid biopsy market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the liquid biopsy market. Competitive analysis of upcoming startups in the liquid biopsy market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall liquid biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of certain liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the liquid biopsy market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd (Switzerland).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONS COVERED
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES
    • 1.5.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 6 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 GROWTH RATE ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
  • 2.8 RISK ASSESSMENT
  • 2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 8 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 9 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 10 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    • FIGURE 11 LIQUID BIOPSY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 12 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 14 LIQUID BIOPSY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 15 LIQUID BIOPSY MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 LIQUID BIOPSY MARKET OVERVIEW
    • FIGURE 16 INCREASING DEMAND FOR MINIMALLY INVASIVE DIAGNOSTIC TECHNIQUES TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
  • 4.2 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 17 ASSAY KITS SEGMENT TO DOMINATE MARKET THROUGHOUT FORECAST PERIOD
  • 4.3 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 18 CIRCULATING TUMOR CELLS SEGMENT TO HOLD LARGEST MARKET SHARE TILL 2029
  • 4.4 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    • FIGURE 19 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO ACCOUNT FOR LARGEST SHARE OF TECHNOLOGY MARKET
  • 4.5 LIQUID BIOPSY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 20 CANCER APPLICATIONS SEGMENT TO RETAIN MARKET DOMINANCE TILL 2029
  • 4.6 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 21 THERAPY SELECTION AND TREATMENT MONITORING TO HOLD LARGEST MARKET SHARES THROUGHOUT FORECAST PERIOD
  • 4.7 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 22 BLOOD SAMPLES TO DOMINATE MARKET TILL 2029
  • 4.8 LIQUID BIOPSY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 23 REFERENCE LABORATORIES TO ACCOUNT FOR LARGEST SHARE
  • 4.9 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 25 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence and prevalence of cancer
    • TABLE 1 INCIDENCE OF CANCER CASES WORLDWIDE, BY TYPE (2022)
    • TABLE 2 PROJECTED INCREASE IN CANCER PATIENTS, BY REGION (2022 VS 2035 VS 2045)
      • 5.2.1.2 Cancer awareness initiatives undertaken by global health organizations
      • 5.2.1.3 Benefits of liquid biopsy over traditional biopsy procedures
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Lower sensitivity of certain liquid biopsy procedures
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing significance of companion diagnostics
      • 5.2.3.2 Growth opportunities in emerging countries
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Unclear reimbursement scenario
  • 5.3 PRICING ANALYSIS
    • TABLE 3 INDICATIVE PRICING OF KEY PLAYERS, BY PRODUCT
  • 5.4 PATENT ANALYSIS
    • FIGURE 26 PATENT ANALYSIS FOR LIQUID BIOPSY (JANUARY 2014-DECEMBER 2023)
    • 5.4.1 LIST OF MAJOR PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 27 VALUE CHAIN ANALYSIS OF LIQUID BIOPSY MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 28 LIQUID BIOPSY MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 TRADE ANALYSIS
    • 5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
    • TABLE 6 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 7 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.8 ECOSYSTEM ANALYSIS
    • FIGURE 29 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS
    • 5.8.1 LIQUID BIOPSY MARKET PLAYERS: ROLE IN ECOSYSTEM
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS
    • TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS (%)
    • 5.10.2 BUYING CRITERIA
    • FIGURE 31 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS
    • TABLE 10 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS
  • 5.11 REGULATORY LANDSCAPE
    • 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.11.2 NORTH AMERICA
      • 5.11.2.1 US
      • 5.11.2.2 Canada
    • 5.11.3 EUROPE
    • TABLE 16 EUROPE: CLASSIFICATION OF DEVICES
    • 5.11.4 ASIA PACIFIC
      • 5.11.4.1 China
      • 5.11.4.2 Japan
    • TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.11.4.3 India
    • 5.11.5 LATIN AMERICA
      • 5.11.5.1 Brazil
      • 5.11.5.2 Mexico
    • 5.11.6 MIDDLE EAST
      • 5.11.6.1 Africa
  • 5.12 TECHNOLOGY ANALYSIS
    • 5.12.1 KEY TECHNOLOGIES
      • 5.12.1.1 Digital Droplet PCR
      • 5.12.1.2 Tagged-Amplicon Deep Sequencing
    • 5.12.2 COMPLEMENTARY TECHNOLOGIES
      • 5.12.2.1 Electrochemical biosensing technology
    • 5.12.3 ADJACENT TECHNOLOGIES
      • 5.12.3.1 Microfluidics-based Devices
  • 5.13 KEY CONFERENCES & EVENTS IN 2024-2025
    • TABLE 18 LIQUID BIOPSY MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 32 REVENUE SHIFT IN LIQUID BIOPSY MARKET
  • 5.15 INVESTMENT & FUNDING SCENARIO
    • FIGURE 33 LIQUID BIOPSY MARKET: INVESTMENT & FUNDING SCENARIO
  • 5.16 CASE STUDY ANALYSIS
    • 5.16.1 CASE STUDY 1: ANALYTICAL VALIDATION OF TARGET SELECTOR CTDNA PLATFORM
    • 5.16.2 CASE STUDY 2: DETERMINING OPTIMAL MUTATION DETECTION MEDIUM

6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 19 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • 6.1.1 PRIMARY NOTES
      • 6.1.1.1 Key Industry Insights
  • 6.2 ASSAY KITS
    • 6.2.1 RECURRENT REQUIREMENTS AND PURCHASES OF ASSAY KITS TO DRIVE GROWTH
    • TABLE 20 KEY PRODUCTS IN ASSAY KITS MARKET
    • TABLE 21 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 22 NORTH AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 23 EUROPE: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 24 ASIA PACIFIC: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 25 LATIN AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO ENSURE MARKET GROWTH
    • TABLE 26 KEY PRODUCTS IN INSTRUMENTS MARKET
    • TABLE 27 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 28 NORTH AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 29 EUROPE: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 31 LATIN AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.4 SERVICES
    • 6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT MARKET GROWTH
    • TABLE 32 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 33 NORTH AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 34 EUROPE: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 35 ASIA PACIFIC: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 36 LATIN AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

  • 7.1 INTRODUCTION
    • TABLE 37 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
  • 7.2 CIRCULATING TUMOR CELLS
    • 7.2.1 EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF TUMOR BURDEN TO DRIVE DEMAND
    • TABLE 38 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 39 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 40 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 41 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 42 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3 CIRCULATING TUMOR DNA
    • 7.3.1 HIGH SENSITIVITY AND SPECIFICITY TO FAVOR ADOPTION
    • TABLE 43 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 44 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 45 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 46 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 47 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.4 CELL-FREE DNA
    • 7.4.1 GROWING APPLICATION OF CFDNA IN PRENATAL SCREENING TO DRIVE GROWTH
    • TABLE 48 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 49 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 50 EUROPE: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 52 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.5 EXTRACELLULAR VESICLES
    • 7.5.1 HIGH STABILITY IN BLOOD CIRCULATION TO ENSURE CONSISTENT GROWTH
    • TABLE 53 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 54 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 55 EUROPE: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 56 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 57 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.6 OTHER CIRCULATING BIOMARKERS
    • TABLE 58 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 59 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 60 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 62 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022-2029 (USD MILLION)

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 63 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 64 NUMBER OF LIQUID BIOPSY SAMPLES TESTED GLOBALLY, BY TECHNOLOGY, 2022-2029 (MILLIONS)
    • 8.1.1 KEY INDUSTRY INSIGHTS
  • 8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
    • 8.2.1 HIGH SENSITIVITY COUPLED WITH HIGHER THROUGHPUT EFFICIENCY TO DRIVE GROWTH
    • TABLE 65 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 66 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 67 EUROPE: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 69 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.3 SINGLE-GENE ANALYSIS USING PCR
    • 8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
    • TABLE 70 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 71 NORTH AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 72 EUROPE: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 73 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 74 LATIN AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022-2029 (USD MILLION)

9 LIQUID BIOPSY MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 75 LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • 9.2 CANCER APPLICATIONS
    • TABLE 76 GLOBAL CANCER INCIDENCE, 2022 VS. 2045, BY REGION
    • TABLE 77 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 78 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 79 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 81 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 82 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • 9.2.1 LUNG CANCER
      • 9.2.1.1 Growing prevalence of lung cancer to propel market growth
    • TABLE 83 GLOBAL LUNG CANCER INCIDENCE, 2022 VS. 2045
    • TABLE 84 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 85 NORTH AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 86 EUROPE: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 87 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 88 LATIN AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.2.2 BREAST CANCER
      • 9.2.2.1 Increasing funding for breast cancer research to spur growth
    • TABLE 89 GLOBAL BREAST CANCER INCIDENCE, 2022 VS. 2045
    • TABLE 90 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 91 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 92 EUROPE: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 94 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.2.3 COLORECTAL CANCER
      • 9.2.3.1 Rising prevalence of colorectal cancer to propel market
    • TABLE 95 GLOBAL COLORECTAL CANCER INCIDENCE, 2022 VS. 2045
    • TABLE 96 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 97 NORTH AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 98 EUROPE: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 99 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 100 LATIN AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.2.4 PROSTATE CANCER
      • 9.2.4.1 Rising patient population to support market growth
    • TABLE 101 GLOBAL PROSTATE CANCER INCIDENCE, 2022 VS. 2045
    • TABLE 102 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 103 NORTH AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 104 EUROPE: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 106 LATIN AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.2.5 MELANOMA
      • 9.2.5.1 Growing need for early diagnosis of genetically mutated tumors to drive market
    • TABLE 107 GLOBAL MELANOMA INCIDENCE, 2022 VS. 2045
    • TABLE 108 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 109 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 110 EUROPE: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 112 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.2.6 OTHER CANCERS
    • TABLE 113 GLOBAL INCIDENCE OF OTHER CANCERS, 2022
    • TABLE 114 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 115 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 116 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 117 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 118 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.3 NON-CANCER APPLICATIONS
    • TABLE 119 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 120 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 121 EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 123 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 124 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • 9.3.1 NON-INVASIVE PRENATAL TESTING
      • 9.3.1.1 Growing demand for NIPT in high-risk pregnancies to drive market
    • TABLE 125 LIQUID BIOPSY MARKET FOR NIPT, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 126 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 127 EUROPE: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 128 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 129 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.3.2 ORGAN TRANSPLANTATION
      • 9.3.2.1 Need for early detection of rejection to improve survival chances to drive growth
    • TABLE 130 LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 131 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 132 EUROPE: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 133 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 134 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.3.3 INFECTIOUS DISEASE TESTING
      • 9.3.3.1 Potential accuracy and efficacy to support development of novel tests
    • TABLE 135 LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 136 NORTH AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 137 EUROPE: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 139 LATIN AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022-2029 (USD MILLION)

10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION

  • 10.1 INTRODUCTION
    • TABLE 140 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
  • 10.2 THERAPY SELECTION
    • 10.2.1 THERAPY SELECTION TO HOLD LARGEST SHARE
    • TABLE 141 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 142 NORTH AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 143 EUROPE: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 144 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 145 LATIN AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.3 TREATMENT MONITORING
    • 10.3.1 EARLY DETECTION OF ALTERATIONS ASSOCIATED WITH DRUG RESISTANCE TO DRIVE ADOPTION
    • TABLE 146 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 147 NORTH AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 148 EUROPE: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 149 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 150 LATIN AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.4 EARLY CANCER SCREENING
    • 10.4.1 POTENTIAL FOR EARLY CANCER DETECTION TO DRIVE MARKET
    • TABLE 151 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 152 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 153 EUROPE: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 154 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 155 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.5 RECURRENCE MONITORING
    • 10.5.1 NEED FOR POST-TREATMENT SURVEILLANCE TO DRIVE DEMAND
    • TABLE 156 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 157 NORTH AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 158 EUROPE: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 159 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 160 LATIN AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)

11 LIQUID BIOPSY MARKET, BY SAMPLE TYPE

  • 11.1 INTRODUCTION
    • TABLE 161 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 162 LIQUID BIOPSY SAMPLES AND APPLICATIONS
    • 11.1.1 KEY INDUSTRY INSIGHTS
  • 11.2 BLOOD SAMPLES
    • 11.2.1 SIMPLICITY, NON-INVASIVENESS TO DRIVE UPTAKE
    • TABLE 163 LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 164 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 165 EUROPE: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 166 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 167 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 11.3 OTHER SAMPLE TYPES
    • TABLE 168 LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 169 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 170 EUROPE: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 171 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 172 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)

12 LIQUID BIOPSY MARKET, BY END USER

  • 12.1 INTRODUCTION
    • TABLE 173 LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 12.2 REFERENCE LABORATORIES
    • 12.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO DRIVE MARKET
    • TABLE 174 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 175 NORTH AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 176 EUROPE: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 177 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 178 LATIN AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 12.3 HOSPITALS & PHYSICIAN LABORATORIES
    • 12.3.1 GROWING NUMBER OF HOSPITALS WORLDWIDE TO BOOST GROWTH
    • TABLE 179 LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 180 NORTH AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 181 EUROPE: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 182 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 183 LATIN AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 12.4 ACADEMIC & RESEARCH CENTERS
    • 12.4.1 GROWING FOCUS ON R&D INTO INNOVATIVE LIQUID BIOPSY TESTS TO FUEL GROWTH
    • TABLE 184 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 185 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 186 EUROPE: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 187 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 188 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 12.5 OTHER END USERS
    • TABLE 189 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 190 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 191 EUROPE: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 192 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 193 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)

13 LIQUID BIOPSY MARKET, BY REGION

  • 13.1 INTRODUCTION
    • TABLE 194 LIQUID BIOPSY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 13.2 NORTH AMERICA
    • TABLE 195 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022
    • 13.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 34 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
    • TABLE 196 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 197 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 198 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 199 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 200 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 201 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 202 NORTH AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 203 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.2.2 US
      • 13.2.2.1 Increasing prevalence of cancer to drive growth
    • TABLE 204 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 205 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 206 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 207 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 208 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 209 US: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 210 US: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.2.3 CANADA
      • 13.2.3.1 Availability of various cancer screening programs to drive growth
    • TABLE 211 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 212 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 213 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 214 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 215 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 216 CANADA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 217 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.3 EUROPE
    • 13.3.1 EUROPE: RECESSION IMPACT
    • TABLE 218 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 219 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 220 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 221 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 222 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 223 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 224 EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 225 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.3.2 GERMANY
      • 13.3.2.1 Favorable government health policies to support market growth
    • TABLE 226 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 227 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 228 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 229 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 230 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 231 GERMANY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 232 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.3.3 UK
      • 13.3.3.1 Rising government healthcare expenditure to propel market growth
    • TABLE 233 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 234 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 235 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 236 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 237 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 238 UK: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 239 UK: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.3.4 FRANCE
      • 13.3.4.1 Rising R&D expenditure to drive market growth
    • TABLE 240 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 241 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 242 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 243 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 244 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 245 FRANCE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 246 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.3.5 ITALY
      • 13.3.5.1 Growing research into novel circulating cancer biomarkers to drive market growth
    • TABLE 247 ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 248 ITALY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 249 ITALY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 250 ITALY: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 251 ITALY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 252 ITALY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 253 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.3.6 SPAIN
      • 13.3.6.1 Focus on personalized medicine to support market growth
    • TABLE 254 SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 255 SPAIN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 256 SPAIN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 257 SPAIN: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 258 SPAIN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 259 SPAIN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 260 SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.3.7 REST OF EUROPE
    • TABLE 261 REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 262 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 263 REST OF EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 264 REST OF EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 265 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 266 REST OF EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 267 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.4 ASIA PACIFIC
    • 13.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 35 ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT
    • TABLE 268 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 269 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 270 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 271 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 272 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 273 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 274 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 275 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.4.2 CHINA
      • 13.4.2.1 Growing public access to advanced healthcare facilities to drive market
    • TABLE 276 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 277 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 278 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 279 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 280 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 281 CHINA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 282 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.4.3 JAPAN
      • 13.4.3.1 Universal healthcare reimbursement policy to fuel growth
    • TABLE 283 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 284 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 285 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 286 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 287 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 288 JAPAN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 289 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.4.4 INDIA
      • 13.4.4.1 Increasing investments in healthcare systems to drive adoption of liquid biopsy products
    • TABLE 290 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 291 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 292 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 293 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 294 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 295 INDIA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 296 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.4.5 REST OF ASIA PACIFIC
    • TABLE 297 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 298 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 299 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 300 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 301 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 302 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 303 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.5 LATIN AMERICA
    • 13.5.1 INCREASING PRIVATE & PUBLIC INVESTMENTS TO DRIVE MARKET
    • 13.5.2 LATIN AMERICA: RECESSION IMPACT
    • TABLE 304 LATIN AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 305 LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 306 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 307 LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 308 LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 309 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 310 LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 311 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.5.3 BRAZIL
      • 13.5.3.1 Improving healthcare infrastructure and supportive regulatory environment to fuel market
    • TABLE 312 BRAZIL: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 313 BRAZIL: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 314 BRAZIL: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 315 BRAZIL: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 316 BRAZIL: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 317 BRAZIL: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 318 BRAZIL: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.5.4 MEXICO
      • 13.5.4.1 Improving accessibility and affordability of healthcare services to support market growth
    • TABLE 319 MEXICO: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 320 MEXICO: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 321 MEXICO: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 322 MEXICO: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 323 MEXICO: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 324 MEXICO: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 325 MEXICO: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.5.5 REST OF LATIN AMERICA
    • TABLE 326 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 327 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 328 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 329 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 330 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 331 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 332 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.6 MIDDLE EAST & AFRICA
    • 13.6.1 INCREASED FUNDING IN RESEARCH TO DRIVE MARKET
    • 13.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 333 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 334 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 335 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 336 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 337 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 338 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 339 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.7 GCC COUNTRIES
    • 13.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE TO DRIVE MARKET GROWTH
    • 13.7.2 GCC COUNTRIES: RECESSION IMPACT
    • TABLE 340 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 341 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
    • TABLE 342 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 343 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 344 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 345 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 346 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)

14 COMPETITIVE LANDSCAPE

  • 14.1 INTRODUCTION
  • 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET
  • 14.3 REVENUE ANALYSIS
    • FIGURE 36 TOP FIVE PLAYERS HAVE DOMINATED LIQUID BIOPSY MARKET IN LAST FIVE YEARS
  • 14.4 MARKET SHARE ANALYSIS
    • 14.4.1 LIQUID BIOPSY MARKET
    • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
    • TABLE 347 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    • 14.5.1 STARS
    • 14.5.2 EMERGING LEADERS
    • 14.5.3 PERVASIVE PLAYERS
    • 14.5.4 PARTICIPANTS
    • FIGURE 38 LIQUID BIOPSY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 14.5.5 COMPANY FOOTPRINT
    • FIGURE 39 LIQUID BIOPSY MARKET: COMPANY FOOTPRINT
    • TABLE 348 LIQUID BIOPSY MARKET: PRODUCT & SERVICE FOOTPRINT
    • TABLE 349 LIQUID BIOPSY MARKET: REGIONAL FOOTPRINT
    • TABLE 350 LIQUID BIOPSY MARKET: APPLICATION FOOTPRINT
  • 14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES
    • 14.6.1 PROGRESSIVE COMPANIES
    • 14.6.2 RESPONSIVE COMPANIES
    • 14.6.3 DYNAMIC COMPANIES
    • 14.6.4 STARTING BLOCKS
    • FIGURE 40 LIQUID BIOPSY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
    • 14.6.5 COMPETITIVE BENCHMARKING
    • TABLE 351 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 352 LIQUID BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
  • 14.7 VALUATION AND FINANCIAL METRICS OF LIQUID BIOPSY VENDORS
    • FIGURE 41 EV/EBITDA OF KEY VENDORS
    • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • 14.8 BRAND/PRODUCT COMPARISON
    • FIGURE 43 BRAND COMPARISON: PCR-BASED LIQUID BIOPSY ASSAYS
    • 14.8.1 QIAGEN
    • 14.8.2 THERMO FISHER SCIENTIFIC INC.
    • 14.8.3 BIO-RAD LABORATORIES, INC.
  • 14.9 COMPETITIVE SCENARIO
    • 14.9.1 PRODUCT LAUNCHES
    • TABLE 353 LIQUID BIOPSY MARKET: PRODUCT LAUNCHES, JANUARY 2021-APRIL 2024
    • 14.9.2 DEALS
    • TABLE 354 LIQUID BIOPSY MARKET: DEALS, JANUARY 2021-APRIL 2024
    • 14.9.3 EXPANSIONS
    • TABLE 355 LIQUID BIOPSY MARKET: EXPANSIONS, JANUARY 2021-APRIL 2024

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
  • (Business overview, Products offered, Recent developments, MnM view, Key strategies, Strategic choices made, and Weaknesses and Competitive threats)**
    • 15.1.1 NATERA, INC.
    • TABLE 356 NATERA, INC.: COMPANY OVERVIEW
    • FIGURE 44 NATERA, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 357 NATERA, INC.: PRODUCTS OFFERED
    • TABLE 358 NATERA, INC.: DEALS
    • 15.1.2 QIAGEN
    • TABLE 359 QIAGEN: COMPANY OVERVIEW
    • FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2023)
    • TABLE 360 QIAGEN: PRODUCTS OFFERED
    • TABLE 361 QIAGEN: PRODUCT LAUNCHES & APPROVALS
    • TABLE 362 QIAGEN: DEALS
    • TABLE 363 QIAGEN: EXPANSIONS
    • 15.1.3 MYRIAD GENETICS, INC.
    • TABLE 364 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
    • FIGURE 46 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 365 MYRIAD GENETICS, INC.: PRODUCTS OFFERED
    • TABLE 366 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES
    • TABLE 367 MYRIAD GENETICS, INC.: DEALS
    • 15.1.4 ILLUMINA, INC.
    • TABLE 368 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 47 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 369 ILLUMINA, INC.: PRODUCTS OFFERED
    • TABLE 370 ILLUMINA, INC.: PRODUCT LAUNCHES
    • TABLE 371 ILLUMINA, INC.: DEALS
    • TABLE 372 ILLUMINA, INC.: EXPANSIONS
    • 15.1.5 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 373 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 48 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
    • TABLE 374 F. HOFFMAN-LA ROCHE LTD.: PRODUCTS OFFERED
    • TABLE 375 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES
    • 15.1.6 THERMO FISHER SCIENTIFIC INC.
    • TABLE 376 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 49 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
    • TABLE 377 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
    • TABLE 378 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES
    • TABLE 379 THERMO FISHER SCIENTIFIC INC.: DEALS
    • TABLE 380 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
    • 15.1.7 GUARDANT HEALTH
    • TABLE 381 GUARDANT HEALTH: COMPANY OVERVIEW
    • FIGURE 50 GUARDANT HEALTH: COMPANY SNAPSHOT (2023)
    • TABLE 382 GUARDANT HEALTH: PRODUCTS OFFERED
    • TABLE 383 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS
    • TABLE 384 GUARDANT HEALTH: DEALS
    • 15.1.8 BIO-RAD LABORATORIES, INC.
    • TABLE 385 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
    • FIGURE 51 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 386 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
    • TABLE 387 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES
    • TABLE 388 BIO-RAD LABORATORIES, INC.: DEALS
    • 15.1.9 EXACT SCIENCES CORPORATION
    • TABLE 389 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
    • FIGURE 52 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 390 EXACT SCIENCES CORPORATION: PRODUCTS OFFERED
    • TABLE 391 EXACT SCIENCES CORPORATION: DEALS
    • 15.1.10 SYSMEX CORPORATION
    • TABLE 392 SYSMEX CORPORATION: COMPANY OVERVIEW
    • FIGURE 53 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 393 SYSMEX CORPORATION: PRODUCTS OFFERED
    • TABLE 394 SYSMEX CORPORATION: DEALS
    • TABLE 395 SYSMEX CORPORATION: EXPANSIONS
    • 15.1.11 BIOCEPT, INC.
    • TABLE 396 BIOCEPT, INC.: COMPANY OVERVIEW
    • FIGURE 54 BIOCEPT, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 397 BIOCEPT, INC.: PRODUCTS OFFERED
    • TABLE 398 BIOCEPT, INC.: PRODUCT LAUNCHES
    • TABLE 399 BIOCEPT, INC.: DEALS
    • 15.1.12 MDXHEALTH
    • TABLE 400 MDXHEALTH: COMPANY OVERVIEW
    • FIGURE 55 MDXHEALTH: COMPANY SNAPSHOT (2022)
    • TABLE 401 MDXHEALTH: PRODUCTS OFFERED
    • TABLE 402 MDXHEALTH: DEALS
    • 15.1.13 PERSONALIS, INC.
    • TABLE 403 PERSONALIS, INC.: COMPANY OVERVIEW
    • FIGURE 56 PERSONALIS, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 404 PERSONALIS, INC.: PRODUCTS OFFERED
    • TABLE 405 PERSONALIS, INC.: PRODUCT LAUNCHES
    • TABLE 406 PERSONALIS, INC.: DEALS
  • 15.2 OTHER PLAYERS
    • 15.2.1 NEOGENOMICS LABORATORIES
    • 15.2.2 EPIGENOMICS AG
    • 15.2.3 ANGLE PLC
    • 15.2.4 MENARINI-SILICON BIOSYSTEMS
    • 15.2.5 LUNGLIFE AI, INC.
    • 15.2.6 VORTEX BIOSCIENCES
    • 15.2.7 BIO-TECHNE
    • 15.2.8 MESA LABS, INC.
    • 15.2.9 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 15.2.10 MEDGENOME
    • 15.2.11 STRAND
    • 15.2.12 FREENOME HOLDINGS, INC.
    • 15.2.13 LUCENCE HEALTH INC.
  • *Details on Business overview, Products offered, Recent developments, MnM view, Key strategies, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS